Antibodies as Drugs: The Art in Antibody Engineering

NIH RePORTER · NIH · R13 · $11,000 · view on reporter.nih.gov ↗

Abstract

ABSTRACT Support is requested for a Keystone Symposia conference entitled Antibodies as Drugs: The Art in Antibody Engineering, organized by Drs. Laura Walker and Paul W. H. I. Parren. The conference will be held in Breckenridge, Colorado from May 5-8, 2024. Antibodies have become the most successful and versatile class of biological drugs with well over 100 therapeutic antibodies approved for human use. Antibody engineering for optimized and novel functionalities is providing unprecedented opportunities in our quest to develop innovative treatments for a wide variety of diseases. In recent years, engineered antibody formats have matured from research to clinical stage molecules with engineered antibodies currently representing about 40% of the 1,000+ antibodies in clinical development. Therefore, this Keystone Symposia conference will review the translation of fundamental insights in both antibody and pathological mechanisms into next generation therapeutics and will discuss the opportunities and challenges ahead.

Key facts

NIH application ID
10906688
Project number
1R13AI183727-01
Recipient
KEYSTONE SYMPOSIA
Principal Investigator
TERRY L. SHEPPARD
Activity code
R13
Funding institute
NIH
Fiscal year
2024
Award amount
$11,000
Award type
1
Project period
2024-04-01 → 2025-03-31